Tumor protein 53 induced nuclear protein 1 (TP53INP1) is a p53 target gene that induces cell growth arrest and apoptosis by modulating p53 transcriptional activity. TP53INP1 interacts physically with p53 and is a major player in the p53-driven oxidative stress response. Previously, we demonstrated that TP53INP1 is downregulated in an early stage of pancreatic cancerogenesis and when restored is able to suppress pancreatic tumor development. TP53INP1 downregulation in pancreas is associated with an oncogenic microRNA miR-155. In the present work, we studied the effects of TP53INP1 on cell migration. We found that TP53INP1 inactivation correlates with increased cell migration both in vivo and in vitro. The impact of TP53INP1 expression on cell migration was studied in different cellular contexts: mouse embryonic fibroblast and different pancreatic cancer cell lines. Its expression decreases cell migration by the transcriptional downregulation of secreted protein acidic and rich in cysteine (SPARC). SPARC is a matrix cellular protein, which governs diverse cellular functions and has a pivotal role in regulating cell-matrix interactions, cellular proliferation and migration. SPARC was also showed to be upregulated in normal pancreas and in pancreatic intraepithelial neoplasia lesions in a pancreatic adenocarcinoma mouse model only in the TP53INP1-deficient animals. This novel TP53INP1 activity on the regulation of SPARC expression could explain in part its tumor suppressor function in pancreatic adenocarcinoma by modulating cellular spreading during the metastatic process.
Tumor protein 53 induced nuclear protein 1 (TP53INP1) is a p53 target gene that induces cell growth arrest and apoptosis by modulating p53 transcriptional activity. TP53INP1 interacts physically with p53 and is a major player in the p53-driven oxidative stress response. Previously, we demonstrated that TP53INP1 is downregulated in an early stage of pancreatic cancerogenesis and when restored is able to suppress pancreatic tumor development. TP53INP1 downregulation in pancreas is associated with an oncogenic microRNA miR-155. In the present work, we studied the effects of TP53INP1 on cell migration. We found that TP53INP1 inactivation correlates with increased cell migration both in vivo and in vitro. The impact of TP53INP1 expression on cell migration was studied in different cellular contexts: mouse embryonic fibroblast and different pancreatic cancer cell lines. Its expression decreases cell migration by the transcriptional downregulation of secreted protein acidic and rich in cysteine (SPARC). SPARC is a matrix cellular protein, which governs diverse cellular functions and has a pivotal role in regulating cell-matrix interactions, cellular proliferation and migration. SPARC was also showed to be upregulated in normal pancreas and in pancreatic intraepithelial neoplasia lesions in a pancreatic adenocarcinoma mouse model only in the TP53INP1-deficient animals. This novel TP53INP1 activity on the regulation of SPARC expression could explain in part its tumor suppressor function in pancreatic adenocarcinoma by modulating cellular spreading during the metastatic process.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in Western countries with an overall 5-year survival rate of o3%. At the time of diagnosis, between 75-85% of patients have unresectable tumors and present metastatic lesions. None of the conventional therapies present a real advantage on the median of survival, which is 5-6 months. Furthermore, most patients who have undergone potentially curative tumor resection die within the first 2 years as a result of local recurrence or distant metastasis. Pancreatic cancer is different from other cancers; a detailed knowledge of genes whose expression is altered during its development may help devising strategies for earlier diagnosis and identifying specific targets to develop new therapeutic interventions. Therefore, in recent decades a great effort has been focused on understanding the molecular alterations that occur in PDAC. One of these alterations that was discovered recently concern the extinction of tumor protein 53 induced nuclear protein 1 (TP53INP1) expression.
TP53INP1 is a pro-apoptotic stress-induced p53 target gene that is able to interact with p53, modulating its transcriptional activity (Tomasini et al., 2002) . TP53INP1 is also known to interact physically with two different kinases: the Homeodomain-interacting protein kinase-2 and the pro-apoptotic Protein Kinase C d contributing to the regulation of p53 activity (Tomasini et al., 2003; Yoshida et al., 2006) . The E2F1 transcription factor, which is also a major player in cell proliferation and apoptosis, is involved in TP53INP1 transcriptional regulation (Hershko et al., 2005) . The TP53INP1 gene encodes two protein isoforms, TP53IN-P1a and TP53INP1b, both of which induce cell cycle arrest and apoptosis when overexpressed (Tomasini et al., 2001) .
PDAC is a genetic and epigenetic disease (Baumgart et al., 2005; Lomberk et al., 2008) . TP53INP1 expression is lost in early stages of pancreatic cancer evolution by a non-mutational mechanism involving the onco-micro-RNA hsa-miR-155 . Interestingly, TP53INP1 restoration strongly reduces pancreatic tumor development . TP53INP1 expression is also lost in other cancers as: rat preneoplastic lesions in liver (Suzuki et al., 2004; Ogawa et al., 2005) and during breast or gastric cancer progression in human (Ito et al., 2006; Jiang et al., 2006) . Altogether, currently available data point to a role of TP53INP1 in cellular homeostasis through its anti-proliferative and pro-apoptotic activities. Hence, loss of its expression may contribute to deregulation of cell proliferation, a hallmark of oncogenesis. However, many evidences also suggest a role for TP53INP1 in cell migration inhibition: (i) TP53INP1 is lost in pancreatic tumor cells that present a very high metastatic potential, (ii) in a previous work, we observed that TP53INP1 restoration in MiaPaCa-2 pancreatic cancer cells inhibits their invasive capacity and (iii) TP53INP1 is a p53 target gene that is able to increase p53 activity by a positive-feedback loop. The p53 is associated with cell migration as it is able to control the expression of genes implicated either directly or indirectly in this process (that is, collagen, fibronectin and smooth muscle a-actin). The p53 can also interact with and regulate the activity of proteins involved in cell migration (like tubulin or F-actin) (Roger et al., 2006) .
Microenvironmental cues, including interactions between cells and the extracellular matrix (ECM), control cellular survival and migration. Pancreatic cancer displays alterations in the normal cell-ECM interactions that increase cell proliferation and invasion. One component of the ECM that presents increased levels in pancreatic tumors is secreted protein acidic and rich in cysteine (SPARC). SPARC is also known as osteonectin or BM-40. It is a 43-kDa secreted extracellular glycoprotein that has important roles in development, tissue healing, remodeling and angiogenesis (Bradshaw and Sage, 2001; Framson and Sage, 2004) . SPARC is expressed in epithelia exhibiting high rates of turnover (Sage et al., 1989; Porter et al., 1995) . It is able to induce an intermediate stage of cellular adhesion with ablation of focal adhesions, to regulate matrix deposition and to induce growth inhibition in different cancer cells (Murphy-Ullrich et al., 1995; Bradshaw and Sage, 2001; Framson and Sage, 2004) . In addition to its physiological role, SPARC has been linked to cancer progression as many cancer types present increased levels of SPARC expression upon invasion or metastasis (Rempel et al., 1998; Loging et al., 2000; Bradshaw and Sage, 2001; Framson and Sage, 2004) . SPARC is highly expressed in a wide range of human malignant neoplasms, and the deregulated expression of SPARC is often correlated with disease progression and/or poor prognosis (Bellahcene and Castronovo, 1995; Porte et al., 1995 Porte et al., , 1998 Porter et al., 1995; Massi et al., 1999; Yamanaka et al., 2001) . It can interact with different ECM proteins like collagens, matrix metalloproteinases and growth factors modulating the cell shape, growth, adhesion and migration.
As we found that TP53INP1 is able to modulate cell migration and to downregulate SPARC expression, we hypothesized that TP53INP1 could modulate cell migration through regulation of SPARC expression. We present in this work data supporting an association between TP53INP1-SPARC and pancreatic cancer cell migration in vitro and in vivo.
Results

TP53INP1 decreases cell migration in vivo
In an attempt to determine whether TP53INP1 could have a role in cell migration, we used a mouse model of skin wound healing (Martin, 1997) . Full-thickness wounds (5-mm) were generated on the dorsal skin of TP53INP1-deficient (TP53INP1À/À) and wild-type (TP53INP1 þ / þ ) animals. The wounds were photographed and the wound surface measured daily. A significant increase in the rate of wound closure was observed from 4 days of wound healing in TP53INP1À/À vs TP53INP1 þ / þ animals, with an average percentage of the wound area of 67 vs 82%, respectively ( Figure 1a) . Pictures representing the wound closure at different times are shown in Figure 1a . Histological analysis of the reepithelialization area at days 3 and 6 showed an increased capacity of the TP53INP1-null TP53INP1 in pancreatic cancer cell migration M Seux et al mice to close excisional wounds (Figure 1b) . Cutaneous wound healing relies not only on cell migration, but also on cell proliferation and wound contraction (Singer and Clark, 1999) . To determine the process, which is associated with the observed differences, we studied the proliferation rate and wound contraction levels. To determine the proliferation rate, we performed an immunohistochemical analysis on wound skin at days 3 and 6 using a specific antibody against the marker of proliferation Ki-67. No difference was observed in the number of Ki-67-positive cells between TP53INP1À/À and TP53INP1 þ / þ animals (data not shown). Concerning wound contraction, the distance between the closest follicles on either edge of the wound provided a marker by which we monitored contraction. No difference was observed in the distance between these follicles at days 3 and 6 among the TP53INP1À/À and TP53INP1 þ / þ animals (data not shown). Therefore, accelerated closure of wound in TP53INP1À/À vs TP53INP1 þ / þ mice may be probably based principally on increased cell migration.
TP53INP1 decreases cell migration in vitro
To confirm the hypothetical association between TP53INP1 and cell migration in cellular models, we studied the migratory ability of TP53INP1 þ / þ vs TP53INP1À/À transformed mouse embryonic fibroblasts (MEFs) and of pancreatic cancer cells MiaPaCa-2 positive or negative for the expression of TP53INP1. Two different technical approaches were used for MEF: (i) a modified Boyden chamber assay and (ii) in vitro wound closure assay. In the modified Boyden chamber assay, different purified ECM matrix proteins were used as attractants, that is, fibronectin-1 (FN1) and vitronectin (Vn). As shown in Figure 2a , TP53INP1À/À MEF exhibited a higher capacity to migrate on FN1 compared with TP53INP1 þ / þ MEF. Similar results were obtained when Vn was used as attractant (data not shown).
In Figure 2b is shown the analysis of TP53INP1 impact on cell migration inhibition in a PDAC cellular model. As pancreatic cancer MiaPaCa-2 cells do not express TP53INP1, we established a TP53INP1- (a) Migration assays were performed in modied Boyden chambers using lters coated with 5 or 10 mg/ml fibronectin-1 (FN1). Cells were added to the upper chambers, and then allowed to migrate toward FN1 for 4 h. (b) Migration of GFP-inducible (GFP) or TP53INP1-inducible (TP53INP1) MiaPaCa-2 cells was measured using a modified Boyden chamber assay using 10 mg/ml FN1 as attractant. GFP or TP53INP1 expression was induced with ponasterone A (PonA) during 48 h before migration assay. (c) Migration of MEF was determined using a wound healing assay in the presence of 10 mg/ml FN1 or 10 mg/ml polylysine (PLL). Empty area was measured and wound closure was calculated comparing area at t ¼ 24 vs area at t ¼ 0. Representative pictures illustrate graph.
TP53INP1 in pancreatic cancer cell migration M Seux et al inducible cell line by restoring TP53INP1 expression only when the cells are treated with ponasterone A (PonA, inductor) as previously reported . Cells were pre-treated for 48 h with PonA or with vehicle (CTL) and then assessed to migrate in the Boyden chamber in presence of PonA or vehicle, respectively, for 4 supplementary hours. As shown in Figure 2b , TP53INP1 expressing cells (PonA treated) show a reduced capacity to migrate on FN1 (42%) compared with TP53INP1 non-expressing MiaPaCa-2 cells (100% as control). Similar results were observed on Vn (data not shown). As control and to evaluate occurrence of artifacts because of protein overexpression, we used green fluorescent protein (GFP)-inducible MiaPaCa-2 cells in the same experimental procedure. No difference was observed between GFP expressing (PonA treated) and GFP non-expressing cells (CTL) (Figure 2b ). Other pancreatic cancer cell lines that do not express TP53INP1 were transfected with TP53INP1 or GFP (as control) and were also assessed to migrate in the Boyden chamber. Gene expression was obtained by transfecting plasmids containing TP53INP1 or GFP complementary DNAs. Similar inhibitory effect on migration was obtained by TP53INP1 expression in PANC1 and Bxpc3 pancreatic adenocarcinoma cells (Supplementary Figure 1) suggesting that TP53INP1 is able to reduce the migration of different pancreatic cancer cell lines.
To confirm the results obtained in the Boyden chamber assay, we performed in vitro wound healing assays on TP53INP1 þ / þ and TP53INP1À/À MEF. Figure 2c shows that TP53INP1À/À MEF migrated more than wild-type only when the cells were plated on FN1. At 24 h, TP53INP1À/À MEF colonized 56% of the initial wound area whereas TP53INP1 þ / þ MEF only 35%. When cells were plated on polylysine (PLL), a neutral matrix used as control, TP53INP1À/À cells migrated as wild-type MEF, about 40% of initial area was colonized. As this type of cell migration requires Ecadherin dependent inter cellular adhesion and MiaPaCa-2 cells do not express E-cadherin, we were unable to perform this assay with MiaPaCa-2 cells.
We also analyzed whether the difference in migration observed in MiaPaCa-2 cells expressing or not TP53INP1, is associated with cell polarization. As cell polarity can modify the migration of cells, MiaPaCa-2 were plated on FN1 and treated or not with PonA to induce the expression of TP53INP1. Cell spreading was analyzed by time-lapse microscopy. We observed a significant difference in the bidimensional migration of the cells in agreement with results described above in this manuscript. MiaPaCa-2 expressing TP53INP1 migrate less (Figure 3a) . We then analyzed this migratory difference in terms of random migration speed (total track length in mm/h) and directional persistence (linear displacement of a cell from its origin/total track length). Our results show that TP53INP1 reduce the migration speed and do not modify the persistence (Figures 3b and c) . No differences were observed in lamelipodia quantity or distribution or in the cellular distribution of organelles (golgi/ endoplamic reticulum orientation (data not shown). These results indicate that TP53INP1 effect on cell migration is not associated with cellular polarity.
TP53INP1 decreases cell invasion in vitro
To determine whether TP53INP1 could also modulate cell invasion, we performed a Matrigel invasion assay with MiaPaCa-2 cells and MEF. The results from Matrigel invasion assay ( Figure 4 ) indicate that TP53INP1 expression strongly inhibited the invasion of MiaPaCa-2 cells ( Figure 4a ) and MEF ( Figure 4b ) by 20 and 6.8 times, respectively, as compared with control (treated with DMSO) and TP53INP1À/À cells. Matrigel composition is complex and similar to the composition of basement membranes containing a small concentration of fibronectin. These results confirm and extend the implication of TP53INP1 on the capacity of cells to migrate and invade and allow us to hypothesize that this TP53INP1 role could depend on ECM composition.
TP53INP1 modulates cell-ECM adhesion
Cell-ECM adhesion is an important process implicated in cell proliferation, cell migration and invasion. The molecular basis of this process is relatively well-known associating integrin activation and cytoskeletal reorganization. To investigate if TP53INP1 can control cell adhesion, we analyzed adhesion of cells expressing or not TP53INP1 on FN1 and Vn. TP53INP1-deficient TP53INP1 in pancreatic cancer cell migration M Seux et al cells showed a reduced ability to adhere compared with wild-type cells only when they were plated on FN1 or Vn at 5 or 10 mg/ml. We observed adhesion of 20% for TP53INP1À/À MEF vs 44% for wild type at 5 mg/ml of FN1 and 76% for TP53INP1À/À vs 100% for wild-type MEF at 10 mg/ml of FN1 (Supplementary Figure 2) .
TP53INP1 induces SPARC downregulation in MiaPaCa-2 cells
To elucidate the molecular mechanism by which TP53INP1 regulates cell migration and invasion, we analyzed the transcriptome of pancreatic cancer cells expressing or not TP53INP1. Two different cellular conditions were used: (i) in vitro cultured MiaPaCa-2 cells and (ii) intrapancreatic injected MiaPaCa-2 cells induced or not for TP53INP1 expression. In the first condition, cells were induced for TP53INP1 expression by PonA treatment during 48 h (vehicle-treated cells were used as control). In the second condition, pancreatic tumors were excised 21 days after intrapancreatic injection of TP53INP1-inducible MiaPaCa-2 cells. TP53INP1 expression was induced with PonA releasing pellets implanted subcutaneously on the mice back 48 h before tumor excision. Placebo-treated animals were used as control. In both cases, total RNA was extracted and analyzed by DNA microchips. Surprisingly, TP53INP1 expression did not affect any gene expression profile in cells cultured in vitro; however, 29 genes were differentially expressed between non-expressing and TP53INP1 expressing tumors in vivo. Among them, 16 genes have already been described as involved in cell migration or in cell-ECM interaction and a strong enrichment in genes implicated in transforming growth factor-b (TGFb) pathway were observed as modulated transcriptionally by TP53INP1 (Supplementary  Table 1 ). SPARC (secreted protein acidic and rich in cysteine/osteonectin/BM40) was the most downregulated molecule when TP53INP1 is expressed in tumors (reduction fold 3.9). To differentiate mouse (peritumoral and infiltrate) from human (MiaPaCa-2) SPARC expression, quantitative real-time reverse transcription PCR were done with mouse and human-specific SPARC primers. As shown in Figure 5a , TP53INP1 expression downregulates SPARC expression only in MiaPaCa-2 intrapancreatic tumors (reduction fold 2.9). Conversely, TP53INP1 expression has no effect on SPARC expression in MiaPaCa-2 cells growing in normal Petridishes. In an attempt to explain the differential behavior presented by these cells growing in Petridishes or in the mouse pancreas, we studied the impact of TP53INP1 expression on SPARC downregulation in vitro in different conditions. We hypothesized that ECM provided by the in vivo environment could be necessary for the effect of TP53INP1 on SPARC expression. For this reason, we studied the TP53INP1 effect on SPARC downregulation in presence of different ECM proteins by quantitative real-time reverse transcription PCR. We found that TP53INP1 expression inhibits SPARC expression only in cells growing on FN1 (reduction fold 1.8) (Figure 5b ). This result was confirmed at protein level by western blotting on secreted SPARC (culture medium, CM). As shown in Figure 5c , TP53INP1 inhibits SPARC expression (and secretion) in MiaPaCa-2 cells only when they are growing on FN1 (reduction fold 2.8).
TP53INP1, pancreatic cancer cell migration and SPARC downregulation SPARC was described as implicated in cell migration, invasion (Robert et al., 2006; Seno et al., 2009) , angiogenesis and in pancreatic cancer (Sato et al., 2003; Infante et al., 2007) . To determine if the role of TP53INP1 in cell migration depends on SPARC downregulation, we developed two different approaches: first, we inhibited SPARC expression with two different specific siRNA (siSPARC1 and siS-PARC2) in TP53INP1 non-expressing MiaPaCa-2 cells (CTL). The second approach was to evaluate the migratory ability of TP53INP1-expressing MiaPaCa-2 cells when they were in contact with the CM from TP53INP1 non-expressing cells (enriched in SPARC) in a Boyden chamber assay.
In Figure 6a , we verified by western blotting that siSPARC1 is able to reduce to 30% SPARC expression in MiaPaCa-2 cells. Similar results were obtained with siSPARC2 (data not shown). The migratory capacity of MiaPaCa-2 cells not expressing TP53INP1 and transfected with the siSPARC1 or siSPARC2 were analyzed in a Boyden chamber assay. SPARC inhibition with siSPARC1 and siSPARC2 reduces by 80 and 60% the migratory capacity of these cells (Figure 6b and data not TP53INP1 in pancreatic cancer cell migration M Seux et al shown). Then, CM from TP53INP1 non-expressing cells (CM DMSO, that is, SPARC-rich medium) or TP53INP1-expressing cells (CM PonA, that is, SPARC-poor medium) was used in a Boyden chamber assay with TP53INP1-induced cells. In Figure 6c , TP53INP1-expressing cells migrate more ( þ 90%) when the medium is rich in SPARC (CM DMSO) compared with SPARC-poor medium (CM PonA). The increase of the secreted SPARC level enhances MiaPaCa-2 cell migration. This strongly indicates that TP53INP1 reduces cell migration by inhibiting SPARC expression in MiaPaCa-2 cells.
TP53INP1 modulates MEF migration by SPARC expression regulation
To confirm these results, we studied TP53INP1 ability to modulate SPARC expression and migration in MEF. First, we quantified SPARC expression in wild-type and TP53INP1-deficient MEF cultured on FN1 or on PLL. As expected, MEF expressing TP53INP1 present reduced SPARC transcription only when they were plated on FN1 whereas TP53INP1-deficient MEF did not exhibit any difference in the expression of SPARC (Figure 7a ). To verify that this transcriptional modulation is followed by a decrease in SPARC protein level, we performed western blot analysis on CM from MEF of both genotypes seeded on plates coated with FN1 or PLL. As shown in Figure 7b , we observed that To determine if the TP53INP1-dependent downregulation of SPARC observed in MEF had consequence on cell migration, we inhibited SPARC expression with two specific siRNAs (siSPARC1-2) in TP53INP1-deficient MEF. First of all, we evaluated SPARC siRNAs efficiency in TP53INP1À/À MEF by western blotting, and we observed that siSPARC1 decreased significantly secreted SPARC protein level (Figure 7c , reduction fold 1.8). Similar results were obtained by transfecting siSPARC2 (data not shown). Cells treated with these siRNAs showed a reduced capacity to migrate (À65%) (Figure 7d and data not shown). These observations strongly suggest that TP53INP1 can reduce MEF migration by SPARC expression downregulation.
SPARC expression is upregulated in the pancreas from KrasG12D-TP53INP1À/À mouse SPARC was previously associated with pancreatic cancer. It was shown to be downregulated in pancreatic cancerous cells by promoter hypermethylation and upregulated in peritumoral fibroblasts (Infante et al., 2007) . Interestingly, Sato et al., 2003 showed that SPARC expression by peritumoral fibroblasts is associated with a bad prognosis for patients with pancreatic cancer. Little is known about the expression of SPARC during pancreatic cancer development, in particular its expression in pancreatic intraepithelial neoplasia (PanIN) lesions. We analyzed the consequences of TP53INP1 deficiency on SPARC expression by immunohistochemistry in a pancreatic cancer mice model based on the expression of the Kras oncogene (KrasG12D) from its endogenous promoter in the TP53INP1 in pancreatic cancer cell migration M Seux et al pancreatic progenitor cells. In these mice, conditional expression of mutant Kras in the pancreas is achieved by a Pdx1-Cre transgene where the Cre recombinase is under the control of the Pdx1 (Pancreatic and Duodenal Homeobox) gene promoter (Hingorani et al., 2003) . KrasG12D; Pdx1 mice were crossed with TP53INP1À/À mice to generate KrasG12D-TP53INP1À/À. As shown in Figure 8a , SPARC expression is upregulated in pancreatic acinar cells from KrasG12D-TP53INP1À/À animals compared with KrasG12D-TP53INP1 þ / þ . Nuclear-positive staining is also visible in PanIN1 lesions in KrasG12D-TP53INP1À/À animals.
SPARC expression is upregulated in pancreatic acinar cells and in the cutaneous wound closure from TP53INP1À/À mouse To study if the increase of SPARC expression in pancreas from KrasG12D-TP53INP1À/À mouse is also observed in animals wild type for Ras, we performed SPARC immunohistochemistry. Results obtained are presented in Figure 8b . We observed an increased expression of SPARC in TP53INP1À/À pancreatic acinar cells. These results indicates that upregulation of SPARC in pancreas depends on TP53INP1 and not on oncogenic Ras activation. Another tissue where SPARC is hypothetically upregulated in absence of TP53INP1 is the skin during wound healing. To verify this hypothesis and to determine the cellular type associated to the expression of SPARC during wound healing, we performed immunohistochemistry with an anti-SPARC monoclonal antibody on sections of skin from wild-type and TP53INP1À/À mice (Figure 8c ). In accordance with previous studies (Reed et al., 1993; Hunzelmann et al., 1998; Bradshaw et al., 2003) , we found SPARC immunoreactivity primarily associated with hair follicles and fibroblasts. Interestingly, the SPARC expression was substantially increased in TP53INP1À/À animals during wound healing. This increase was observed in hair follicles and fibroblast surrounding the wounds. This results support our hypothesis indicating that in absence of TP53INP1, the accelerated wound closure could depend, at least in part on the upregulated expression of SPARC.
Discussion
In a previous study, we showed that TP53INP1 displays a tumor suppressor activity regulating proliferation and apoptosis in pancreatic cancer cells . In this work, we demonstrate for the first time that TP53INP1 is also able to reduce cell migration. The acquisition of a migratory phenotype is an important characteristic of PDAC cells from the first stage in the tumor formation. TP53INP1 expression is lost very early during pancreatic tumorigenesis and we hypothesized that this could be responsible for, at least in part, the strong metastatic phenotype of pancreatic cancer cells.
We first showed that TP53INP1 deficiency is responsible for accelerated wound closure and we hypothesized that TP53INP1 deficiency could activate the migration of skin fibroblasts (Figure 1) .
Using two different cellular models expressing or not TP53INP1 ((i) transformed MEFs (MEF TP53INP1 þ / þ and TP53INP1À/À) and (ii) TP53INP1-inducible MiaPaCa-2 cells), we tested their migratory ability in TP53INP1 in pancreatic cancer cell migration M Seux et al different assays and we observed a correlation between the absence of TP53INP1 expression and the increased migratory capacity of cells. We observed a FN1 dosedependent behavior in TP53INP1À/À fibroblast whereas TP53INP1 þ / þ MEF migrated at similar level in different FN1 concentrations (Figure 2) . These results confirm in vitro a TP53INP1 role in cell migration. We show that TP53INP1 affect cell migration reducing the migration speed of cells (Figure 3) . To elucidate the molecular mechanism subjacent the TP53INP1 role in cell migration, we performed transcriptomic analysis on MiaPaCa-2 cells expressing or not TP53INP1. Surprisingly, TP53INP1 expression did not affect gene expression in cells cultured in vitro, but 29 genes were differentially expressed in these cells if they grew as intrapancreatic tumors. Among them, 16 genes have already been described as involved in cell migration or in cell-ECM interaction (Supplementary Table 1 ). SPARC is one of these genes and we decided to further characterize its association with TP53INP1.
Interestingly, SPARC was associated with cell migration and wound healing. Differing data have been published concerning SPARC role in wound closure. Basu et al., 2001 showed that the deficiency of SPARC is responsible for cutaneous closure defect principally based on a lower fibroblast migration. Conversely, Bradshaw et al., 2002 Bradshaw et al., , 2003 showed that SPARC deficiency is associated with an accelerated closure of cutaneous wound and they found decreased collagen content and enhanced contractibility of wound in SPARC-deficient mice. In our study, we did not observe differences in wound contraction neither in re-epithelisation. We concluded that cell migration could explain the enhanced wound healing observed in TP53INP1-deficient mice (Figure 1 ). We hypothesized that higher expression of SPARC resulting of TP53INP1 deficiency could be associated with the difference observed in wound closure in our model. This hypothesis was confirmed in vitro, but no direct evidence allowed us to conclude that the difference observed on wound healing in vivo depends exclusively on SPARC expression.
We also showed that TP53INP1 is able to reduce SPARC expression when pancreatic cancer cells grow on plates that are coated with ECM ( Figure 5 ). ECM forms part of the tumor microenvironment and is secreted by cancer and stromal cells. Murine pancreatic cancer cells injected orthotopically into SPARC-null mice grow larger and metastasize more frequently than those in wild-type mice, thus highlighting the importance of SPARC function and ECM composition in tumor progression (Arnold et al., 2008) . The fact that the tumor cells, but not the infiltrating stroma cells, express and secrete SPARC in the aforementioned studies also supports the observation that the effect of SPARC on tumorigenesis is context-and cell-type dependent (Brekken et al., 2003; Puolakkainen et al., 2004) .
Microenvironment of tumor cell seems to be implicated in SPARC regulation by TP53INP1 suggesting its implication in a dialogue between the cancerous cells and tumor stroma ( Figure 5 ). Using specific primers for human SPARC in pancreatic cancer cells or mouse SPARC for the infiltrating mouse fibroblast, we demonstrated that TP53INP1 regulate SPARC expression in cancer cells and not in the infiltrate. We hypothesized that in human PDAC downregulation of TP53INP1 induces the expression of SPARC and increases the migration of pancreatic cancer cells. Accordingly, SPARC has already been described as highly expressed in PDAC at both primary and metastatic sites (Guweidhi et al., 2005; Ryu et al., 2001 ) and patients whose tumor-associated stroma express high levels of SPARC, have a worse prognosis (Infante et al., 2007) . in vitro, exogenous SPARC enhances, while SPARC knockdown reduces, invasion of human pancreatic cancer cells (Guweidhi et al., 2005) . On the other hand, many authors describe SPARC downregulated in the malignant cells, but upregulated in the intra-and peritumoral stroma. Sato et al., 2003 reported rarely immunohistochemical labeling in primary pancreatic cancer cells, but detected SPARC in the stromal fibroblasts immediately adjacent to the neoplastic epithelium. In the same way, other authors have shown that the methylation of the SPARC gene occurs in 91% of human infiltrating pancreatic adenocarcinoma, 88% of primary human pancreatic carcinoma xenografts and 94% of human pancreatic cancer cell lines (Brune et al., 2008) .
In contrast to our result Chen et al., 2010 reported recently that SPARC inhibits both Panc-1 and MiaPaCa-2 cell migration. The discrepancy may result from differences in the experimental procedures setting. Indeed, in the assay performed by Chen et al., the difference observed in presence of SPARC could be because of a difference in cell proliferation as exogenous SPARC has been associated to a significant reduction of pancreatic Panc1 and AsCP1 cells proliferation (Sato et al., 2003) . In Chen's work, the number of migrating cell was analyzed after 72 h of incubation allowing multiple cell replications. By contrast, to avoid possible differences associated to cell proliferation, our experiments were done only 4 h after plating the cells in the Boyden chamber (Figure 2 ) and 6 h (for MEF) or 24 h (for MiaPaCa-2 cells) in Matrigel assay (Figure 4) . One other possible explanation to this discrepancy could also come from the fact that TP53INP1 modulates the expression of others genes (Supplementary Table I ) that can influence the final result of SPARC action on cell migration.
The complexity of published data strongly suggests that the role of SPARC is multifaceted given that the effect of this protein depends on three main factors: (i) the concentration, (ii) the type of cells and (iii) the microenvironment composition. In fact, SPARC can display different effects on cell adhesion, proliferation and migration depending on its concentration (Rempel et al., 2001) . For example, at high concentration SPARC is a strong de-adhesive molecule avoiding cell migration whereas at intermediate concentration, SPARC can increase cell migration. SPARC can display different actions on different cell types (endothelial cells TP53INP1 in pancreatic cancer cell migration M Seux et al or tumor cell) . Finally, SPARC activity depends on its different interactors that are present in the cellular microenvironment (Bradshaw and Sage, 2001) .
We also showed in this work a correlation between pancreatic cancer development and SPARC expression. Recent studies investigating SPARC expression in human pancreatic tissues reported high levels of SPARC in the stromal fibroblasts, whereas SPARC was often absent in cancer cells (Guweidhi et al., 2005; Infante et al., 2007) . Interestingly, co-culture of fibroblasts in the presence of PDAC cells cause increased SPARC expression in fibroblasts showing that SPARC transcription in fibroblasts can be upregulated in response to soluble mediators secreted by pancreatic cancer cells (Sato et al., 2003) . Taking that into account, we hypothesize that in pancreatic precancerous lesions, SPARC could be transcriptionally activated following TP53INP1 translational down egulation caused by miR-155. As pancreatic cancer evolves, two independent phenomena take place; (1) desmoplasia and (2) SPARC promoter hypermethylation. Then, PDAC cells present SPARC downregulation, but secrete soluble factors that induce SPARC expression in stromal cells. SPARC presence probably maintains, at this point, high migratory potential of PDAC cells (Figure 9 ). Another interesting observation comes from the fact that p53 activity is lost in more than 50% of human PDAC. However, p53 mutation appears in later-stage PanINs that have acquired significant features of dysplasia. In these more advanced PanINs, the selective pressure to eliminate p53 may stem in part from a collective accumulation of genetic damage. We published before that TP53INP1 downregulation take place at early-stage PanINs preceding p53 mutation. These observations points toward a p53 independent downregulation of TP53INP1.
In this work, we also observed that nine genes modulated by TP53INP1 are implicated in TGFb pathway (Supplementary Table 1 ). Interestingly, SPARC was previously associated with the regulation of TGFb (Schiemann et al., 2003) . TGFb is a master regulator of wound-healing and fibrosis by inducing the synthesis of several ECM proteins including collagen and FN1 (Verrecchia and Mauviel, 2007) . Ample data demonstrate that TGFb induces SPARC expression (Wrana et al., 1991; Ford et al., 1993; Reed et al., 1994) . However, there is also evidence that SPARC regulates the expression and activity of TGFb, suggesting that there is a reciprocal regulatory feedback loop between SPARC and TGFb.
TP53INP1 capacity to reduce cell migration could represent an attractive therapeutic possibility as TP53INP1 can, by this way, modulate critical advanced tumor phenotypes like cell spreading. SPARC represents the first target identified associated with cell migration to be modulated by TP53INP1.
Materials and methods
Cutaneous wound closure TP53INP1 wild-type or deficient mice were as described in Gommeaux et al., 2007 . In this work, C57BL/6 mice backcrossed by nine generations were used. The genotypes of the mouse colony were monitored by PCR using genome-specific primers on purified tail DNA. Two circular wounds (diameter 5 mm) per animal were generated in the back of anesthetized mice. Wound areas were measured everyday during 7 days on photography with ImageJ software. Three measurements were taken for each wound.
Histological analysis of cutaneous wounds
Sections of wounds from wild-type and TP53INP1-null mice were deparaffinized and subjected to antigen retrieval with a 20-min incubation in steaming citrate buffer (0.1 M) as recommended for the Ki-67 antibody (Dako; Carpinteria, CA, USA). Sections were blocked in 2% normal goat serum and were incubated in primary antibody for 1 h. The Ki-67 antigen was detected with a secondary antibody conjugated to biotin and the signals for both Ki-67 and PCNA were amplified by incubation with the ABC Elite kit (Vector Labs; Burlingame, CA, USA). Horseradish peroxidase activity associated with the primary antibodies was visualized with 3,3-diaminobenzidine substrate with or without nickel enhancement. Slides were counterstained with Hematoxylin and Eosin (H & E) (Ted Pella; Redding, CA, USA). Stained sections were viewed on a Nikon microscope (Tokyo, Japan).
Cell culture and treatment GFP-and TP53INP1-inducible MiaPaCa-2 cells and E1A/ ras V12 transformed MEF were generated from C57BL/6 mice as described in Gironella Molecular model describing miR-155-TP53INP1-SPARC-cell migration association in PDAC development. In normal pancreas, low expression of miR-155 allow a slightly expression of TP53INP1. In this condition, SPARC is expressed at low levels and cell migration remains weak. During pancreatic cancer evolution (pancreatic intraepithelial neoplasia (PanIN) lesions), miR-155 is upregulated blocking the translation of TP53INP1. In these conditions, the SPARC downregulation exerted by TP53INP1 is missed and upregulated expression of SPARC induces cell migration. In well-established PDAC, miR-155 remains high, TP53INP1 expression is completely blocked and SPARC gene promoter became hypermethylated avoiding the expression of SPARC. In this case, cellular migration remains high because the high expression of SPARC from stromal cells. 
Migration assay
Migration assays were performed using modified Boyden chambers (NeuroProbe Inc, Bethesda, MD, USA) with 8-mm pore polycarbonate Nucleopore membranes (Costar, Cambridge, MA, USA). The undersurface of the membrane was coated with FN1 (Sigma, St Louis, MO, USA) or Vn in phosphate-buffered saline (5 or 10 mg/ml) for 16 h at 4 1C or PLL (10 mg/ml). For details see Supplementary Materials and methods.
Wound healing assay MEF, 2 Â 10 6 , were plated overnight on 6-wells plates precoated with FN1 or PLL at 10 mg/ml. Cells were treated with mitomycin C at 5 mg/ml (Sigma) and mechanically wounded. After 24 h, migration was evaluated measuring the empty area with ImageJ software (% in regard to initial empty area).
Time-lapse microscopy
Single cell suspension (MiaPaCa-2 cells, treated with PonA or DMSO (CTL) for 48 h or TP53INP1 þ / þ and À/À MEF) were seeded in 24-well plates precoated with 10 mg/ml FN1 at the density of 10 5 cells per plate. Cells were allowed to adhere and spread for 2 h. Plates were then placed in a temperature and CO 2 -controlled chamber mounted on a Nikon TE2000 inverted microscope. Images were captured every 10 min for a total observation period of 5 h using a Cool SnapHQ camera (Princeton Instruments, Trenton, NJ, USA) through a Â 10 objective lens. Cells were tracked and migration speed (in mm/h) and persistence (displacement/track length, where displacement is the distance from the start to end point for each cell) were determined using ImageJ analysis software (http://rsb.info.nih.gov/ij).
Intrapancreatic tumors generation
Nude mice were anesthetized by intraperitoneal injection of a ketamine-xylazine mix (150-7.5 mg/kg) and the abdomen was opened by a small lateral incision. The stomach, the spleen and the pancreas were placed outside the body to allow intrapancreatic injection of 10 millions of cells (in 50 ml of DMEM 10% FBS). Vehicle or PonA releasing pellets (Innovative Research of America, Sarasota, FL, USA) were implanted subcutaneously on mice for 48 h. Animals were killed and opened to excise intrapancreatic tumors.
Quantitative real-time reverse transcription PCR The complementary DNA were synthesized from 1 mg total RNA with the ImProm-II Reverse transcription system (Promega, Madison, WI, USA) using oligodT as primer and according to the manufacturer 0 s procedure. PCR reaction mixes were assembled using the SYBR Premix Ex Taq (Takara Biotechnology, Shiga, Japan) according to manufacturer 0 s instructions. For PCR conditions and primers see Supplementary Materials and methods.
Microarray
The experiment was performed on U133 2.0 Plus Genechip (Affymetrix, Santa Clara, CA, USA), as previously described (Vasseur et al., 2003) , and analyzed with the Microarray Suite 5.0 software (Affymetrix).
Western blot analysis
Antibodies for immunoblotting experiments included mouse monoclonal anti-SPARC (diluted 1/1000) (Haematologic Technologies Inc., Essex Junction, VT, USA), mouse monoclonal anti-b-tubulin (diluted 1/1000) (TUB-2.1 from SigmaAldrich) and anti-mouse horseradish peroxidase-conjugated IgG (diluted 1/300 traditional system, 1/1000 SNAP system) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Secondary antibodies were detected with the ECL chemiluminescence reaction kit (Amersham Pharmacia Biotech, Buckinghamshire, UK) in accordance to the manufacturer's instructions. For details see Supplementary Materials and methods.
